Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease
Open Access
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 14 (8) , 101115
Abstract
No abstract availableKeywords
Funding Information
- Prostate Cancer Foundation
- University of Surrey
This publication has 128 references indexed in Scilit:
- TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancerProceedings of the National Academy of Sciences, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Mechanism of Androgen Receptor Antagonism by Bicalutamide in the Treatment of Prostate CancerBiochemistry, 2011
- A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activitiesThe Prostate, 2011
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Non-competitive androgen receptor inhibition in vitro and in vivoProceedings of the National Academy of Sciences, 2009
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomicsBioorganic & Medicinal Chemistry Letters, 2008
- Cell- and gene-specific regulation of primary target genes by the androgen receptorGenes & Development, 2007
- Stat3 activation of NF-κB p100 processing involves CBP/p300-mediated acetylationProceedings of the National Academy of Sciences, 2006
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003